Media stories about Veracyte (NASDAQ:VCYT) have trended positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a daily sentiment score of 0.31 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 50 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- -$0.25 Earnings Per Share Expected for Veracyte, Inc. (NASDAQ:VCYT) This Quarter (americanbankingnews.com)
- Veracyte : Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer (4-traders.com)
- Sony Wants Anne Hathaway For ‘Barbie’ Live-Action Film (healthcaremenu.net)
- Veracyte (VCYT) Says Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer (streetinsider.com)
- Veracyte Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer (finance.yahoo.com)
Veracyte (NASDAQ VCYT) traded up 1.09% on Friday, hitting $8.38. The stock had a trading volume of 67,166 shares. The company has a 50-day moving average of $7.99 and a 200 day moving average of $8.16. Veracyte has a 12 month low of $4.82 and a 12 month high of $9.71. The company’s market cap is $283.83 million.
Veracyte (NASDAQ:VCYT) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.24) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.24). The business had revenue of $16.43 million for the quarter, compared to analysts’ expectations of $18.09 million. Veracyte had a negative return on equity of 66.79% and a negative net margin of 43.40%. On average, analysts predict that Veracyte will post ($0.92) EPS for the current fiscal year.
VCYT has been the subject of several research reports. Cantor Fitzgerald set a $13.00 price target on shares of Veracyte and gave the company a “buy” rating in a research report on Thursday, May 4th. Janney Montgomery Scott reissued a “buy” rating and issued a $15.00 target price on shares of Veracyte in a report on Wednesday, June 28th. Finally, BidaskClub raised shares of Veracyte from a “strong sell” rating to a “sell” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $11.83.
ILLEGAL ACTIVITY WARNING: “Favorable News Coverage Somewhat Likely to Impact Veracyte (NASDAQ:VCYT) Stock Price” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/07/28/veracyte-nasdaqvcyt-given-media-sentiment-score-of-0-31-updated-updated-updated.html.
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.